[HTML][HTML] The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients …
O Mulas, E Abruzzese, L Luciano, A Iurlo, I Attolico… - Annals of …, 2024 - Springer
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated …
O Mulas, E Abruzzese, L Luciano, A Iurlo… - ANNALS OF …, 2024 - iris.univr.it
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated …
O Mulas, E Abruzzese, L Luciano… - Annals of …, 2024 - pubmed.ncbi.nlm.nih.gov
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated …
O Mulas, E Abruzzese, L Luciano, A Iurlo… - ANNALS OF …, 2024 - cris.unibo.it
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated …
O Mulas, E Abruzzese, L Luciano, A Iurlo… - ANNALS OF …, 2024 - air.unimi.it
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated …
O Mulas, E Abruzzese, L Luciano, A Iurlo… - ANNALS OF …, 2024 - iris.uniroma1.it
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
[HTML][HTML] The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients …
O Mulas, E Abruzzese, L Luciano, A Iurlo… - Annals of …, 2024 - ncbi.nlm.nih.gov
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated …
O Mulas, E Abruzzese, L Luciano, A Iurlo… - Annals of …, 2023 - europepmc.org
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated …
O Mulas, E Abruzzese, L Luciano, A Iurlo… - ANNALS OF …, 2023 - iris.unica.it
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated …
O Mulas, E Abruzzese, L Luciano, A Iurlo… - Annals of …, 2023 - europepmc.org
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …
experience arterial occlusive events (AOEs). It is currently recommended to thoroughly …